Trichostatin A (TSA)

For research use only.

Catalog No.S1045

126 publications

Trichostatin A (TSA) Chemical Structure

Molecular Weight(MW): 302.4

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 324 In stock
USD 247 In stock
USD 447 In stock
USD 870 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Trichostatin A (TSA) has been cited by 126 publications

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.
Targets
HDAC [1]
(Cell-free assay)
~1.8 nM
In vitro

Trichostatin A inhibits the proliferation of eight breast carcinoma cell lines including MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3 with mean IC50 of 124.4 nM (range, 26.4-308.1 nM), with more potency against cell lines that express ERα than the ERα-negative cell lines. Trichostatin A inhibits HDAC activity similarly in all the breast cancer cell lines with mean IC50 of 2.4 nM (range, 0.6-2.6 nM), and results in pronounced histone H4 hyperacetylation. [1] Unlike Trapoxin (TPX) and Chlamydocin which potently inhibit HDAC1 or HDAC4 but not HDAC6, Trichostatin A inhibits these HDACs to a similar extent with IC50 of 6 nM, 38 nM, and 8.6 nM, respectively. [2] Trichostatin A (100 ng/mL) treatment induces the expression of transforming growth factor β type II receptor (TβRII) in MIA PaCa-2 cells through the recruitment of p300 and PCAF into a Sp1-NF-Y HDAC complex that binds the DNA element of TβRII promoter, which is associated with a concomitant acetylation of Sp1 and an overall decrease in the amount of HDAC associated with the complex. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEK 293 NWTDbpJ7TnWwY4Tpc44hSXO|YYm= NV\CU2ZCOC55zszN NEnzWFEzPGh? MXXleIhidm:u MnPT[Y5p[W6lZYOgSW5iSyCjY3X0fYxifGmxbjDhcoQhcW6lcnXhd4V{KEWQYVOgZYJ2dmSjbnPlJIlvKHSqZTD0c5RidCClZXzsJIx6e2G2ZTDhcoQh[XRidHjlJINmdGxic4Xy[oFk\Q>? MkL4NlU4QDdyN{m=
TE13 M2nIVmZ2dmO2aX;uJGF{e2G7 M3TtNlAvO87:TR?= MlnNNlRp MXv1dE1z\We3bHH0[ZMhWkGVU1[1RUBt\X[nbB?= MoXzNlU2Pzl4NkW=
TE13 Mln0RZBweHSxc3nzJGF{e2G7 NHHKbXAxNjQQvF2= Mm\0NlRp NGfOR3hqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:w Mo\INlU2Pzl4NkW=
MEFs MV\GeY5kfGmxbjDBd5NigQ>? M4TzPFXPxE1? NYPqZoc5OT[q M3;5Nolv[3KnYYPld{B1cGViRWDFR{BifHSjY3jt[Y51NCCWaYKg[IVtcX[ncomgZY5lKHSqZTDl[oZq[2mnbnP5JI9nKHCnZHXzeIFtKG[xcn3heIlwdg>? MnzzNlU1QDJ4M{S=
SW480  NW[0b2ExTnWwY4Tpc44hSXO|YYm= NV7SXIpvOC5zzszN NVHhVGdsPDiq Mn3nSG1UVw>? MXry[ZZmenOnczDFUXQ> NVfWTZE6OjV2M{S5PVc>
PC3  NHjCd5ZHfW6ldHnvckBCe3OjeR?= MWKwMlHPxE1? NE\MfIM1QGh? M1;zdWROW09? M{H5V5JmfmW{c3XzJGVOXA>? NYDSZ5V6OjV2M{S5PVc>
SW480  M1:0c2Z2dmO2aX;uJGF{e2G7 NFj0No8xNjIQvF2= MVi0PIg> M4\HWWROW09? M4H1[YF1fGWwdXH0[ZMhcW64YYPpc44h[W6mIH3p[5JifGmxbh?= M1u1NFI2PDN2OUm3
PC3  M1zEbmZ2dmO2aX;uJGF{e2G7 NGrOPFMxNjIQvF2= Mnm1OFhp M{fWOmROW09? Mle1ZZR1\W63YYTld{Bqdn[jc3nvckBidmRibXnndoF1cW:w M1rEfFI2PDN2OUm3
SW480  MUHGeY5kfGmxbjDBd5NigQ>? MWewMlHPxE1? Mon4OFhp MWLEUXNQ M1HucIlv\HWlZYOgbY5kemWjc3Wgc4YhUESDQ{GgZY5lKEiGQVOyJI9vKFOudXeg[4Vv\XNicILvcY91\XJ? MY[yOVQ{PDl7Nx?=
PC3  M3joT2Z2dmO2aX;uJGF{e2G7 M4myfVAvOc7:TR?= MXK0PIg> NYLrfWhETE2VTx?= NWXnWox{cW6mdXPld{BqdmO{ZXHz[UBw\iCKRFHDNUBidmRiSFTBR|Ihd25iU3z1[{Bo\W6nczDwdo9ud3Snch?= NYG1OHV5OjV2M{S5PVc>
A431 M3raeWFxd3C2b4Ppd{BCe3OjeR?= M3LOcFIwOTBxNUCvNVAxdk1? MoHzOFhp MWfEUXNQ MUPpcohq[mm2czD0bIUh[2WubDDndo94fGh? M2jqOVI2OzdzME[5
A431 NWe2eINDTnWwY4Tpc44hSXO|YYm= M3XNV|Uxdk1? NVLGPG5IOi94L{GyM|I1cA>? NXvwNJVHTE2VTx?= M1fnO4FkfGm4YYTld{BxOjFiYX7kJIlvcGmkaYTzJGFVTjNiZYjwdoV{e2mxbh?= NVLyTHV[OjV|N{GwOlk>
MDA-MB-231 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXSTHQxNTZyMH7N M3vpelI1cA>? M{fTfGROW09? NVi0TFByUUN3MDDv[kAyODCwTR?= NY[2[mtxOjVzOUK3NlE>
MCF7 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofpNE03ODCwTR?= NYHHWWd6OjSq NXf5S4N3TE2VTx?= MYDJR|UxKG:oIEe1cm0> NEXidVkzPTF7MkeyNS=>
SKOV-3 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;IUVEuOTEQvF2= Ml7pNlRp NGjTOZNFVVOR M2\ZPWlEPTBib3[gOU43|ryP MoTrNlUyPjl2OUG=
A549 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfOe4kyNTFyzszN Mkn2NlRp NFm1N4hFVVOR M3OxNmlEPTBib3[gN{4z|ryP NYKwW3JFOjVzNkm0PVE>
SKOV-3 NUnj[pJpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2raN|AvOS1zzszN NGC4doM1QGh? MVjEUXNQ M1TwRWlEPTBib3[gNE44|ryP NFznbZQzPTF4OUS5NS=>
A549 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojqNE4yNTIQvF2= MlrSOFhp MlfPSG1UVw>? NG\WcHRKSzVyIH;mJFAvOjkQvF2= NVrwN3BNOjVzNkm0PVE>
SKOV-3 M3WwSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXv6XmFEOC5yMT2wMlnPxE1? M3vkblczcA>? Mm[1SG1UVw>? NXzafGliUUN3MDDv[kAxNjN{zszN MV[yOVE3QTR7MR?=
A549 MlThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\MNVAvODFvMD65{txO NI[2d4U4Omh? NHXVNJpFVVOR NYryN2JHUUN3MDDv[kAxNjB4zszN M3S0V|I2OTZ7NEmx
HeLa NFG3VHVHfW6ldHnvckBCe3OjeR?= M2e3dFI2OG6P M4TDWVE3cA>? MVPEUXNQ NUj1bXNGcW6lcnXhd4V{KEO\UEHBNUBuWk6DIHX4dJJme3Orb39CpC=> NXPwblBsOjVzMU[2PFg>
CNE2 NHPvb3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX:xNFAuPjBybl2= M4nQb|I1NzR6L{eybC=> NV3RRpNRcW6qaXLpeJMhfGinIIDyc4xq\mW{YYTpc44hcW5iYTD0bY1mNSCjbnSg[I9{\S2mZYDlcoRmdnRibXHucoVz MVyyOFk3QTlyMR?=
PC3 Mn;pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLKV|VVOTByLUGwNFBvVQ>? MnjrNlRp NIriPZVKSzVyIH;mJFMxOG6P NH\HXY4zPDh3NE[1PC=>
LNCaP MmDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLTV5JiOTByLUGwNFBvVQ>? MlvzNlRp MnfZTWM2OCCxZjCzNFBvVQ>? M13w[FI1QDV2NkW4
HeLa  NYOwd5lQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvaPYN[Os7:TR?= M4TlR|Q5cA>? NHi3U4Fl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgZYJwfXRiMkWl M4DoSFI1QDR4MUO1
HMEC-1  M2LxSWZ2dmO2aX;uJGF{e2G7 NEn5RYE{ODCwTR?= MWiyOIg> NX2y[2QycW6lcnXhd4V{KGW6cILld5Nqd25ib3dCpHZGT0[UM9MgcXJPSQ>? M37uVVI1PzFyNkOx
HeLa NIXXV2tHfW6ldHnvckBCe3OjeR?= NVPyRpE2OW2P MV6wMlVp M3PzXoFjd2yrc3jld{B1cGVidH;0ZYwhUESDQzDhZ5Rqfmm2eR?= Ml3aNlQ4ODd2N{S=
ACP02 NGn6OJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvnNlUxNzN3MD:1NFBvVQ>? M2fNT|I1cA>? NXi3[Ho4\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JI9nKGGycILvfIlu[XSnbImgO|DDqCViYYSgNlUxyqCwTR?= NEfuOIozPDZ4OEW0Oy=>
ACP03 NInIeHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWe0OolWOjVyL{O1NE82ODCwTR?= NU\EfXdyOjSq NETibIdl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgc4Yh[XCycn;4bY1ifGWueTC3NOKhLSCjdDCyOVDDqG6P NXPrd|NvOjR4Nki1OFc>
U87 GBM MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXzeY9HOTByL{OwNE82ODBibl2= NWi1dJlUPzJiaB?= MYOxNFAmKGW2aHHuc4w> MUfy[YR2[2W|IH3lZY4h[2WubDDueY1j\XJiYomgN|EtKDV2LDDhcoQhPTkEoDW= MWKyOFQ3PDh2MR?=
U87 GBM M3nzWWZ2dmO2aX;uJGF{e2G7 MlvTNVAxNzVyMDDOcS=> NHTKSII1QCCq NEC2fGQyODBnIHX0bIFvd2x? MUXJcoR2[2W|IGPlcoV{[2WwY3WtUIls\SCDbITldoF1cW:wczDpckBPfWOuZXHyJG1wenCqb3zv[5k> MVOyOFQ3PDh2MR?=
RPE M4i0b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDOXpUxNjJxMD60M|AvQC9zIN88US=> NHPsb5kzPC92OD:3NkBp MXXEUXNQ Mlv0bY5pcWKrdIOgeIhmKHC{b3zp[oVz[XSrb36gZpkh[2WubDDjfYNt\SCjcoLld5Q> MV:yOFQ2PjZyMh?=
HT29  MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TSR|E5OCCwTR?= Mlv5O|IhcA>? M2r6cmlEPTBib3[gNVgxKG6P M1;VclI1OzZ6Mk[1
hMSCs MVXGeY5kfGmxbjDBd5NigQ>? MWm2MlI2KG6P NGPqbW8zPCCq MVLEUXNQ MoO0d5Ri[mmuaYrld{BJcXO2b37lJGFk\XS7bHH0bY9vKGGwZDD0bIUhTXiycnXzd4lwdiCxZjDQcJVzcXCxdHXueEBI\W6ncx?= MXOyOFMyOjN3Nh?=
Huh7  NHPCSJRHfW6ldHnvckBCe3OjeR?= NVvvZ5M6OC5zL{CuOU8yNjBizszN NGO0bVQzPGh? M{jX[JN2eHC{ZYPz[ZMhYVSKRFOyJIdmdmViZYjwdoV{e2mxbh?= NFG4cIIzPDJ4OU[3Ni=>
SKOV3 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXKwMlA2NTJizszN NHfaWnQyOC9{ND:0PEBp MmS0SG1UVw>? MVXt[YRq[XSnczDndo94fGhiYYLy[ZN1KGmwIHGgZ49v[2WwdILheIlwdi1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? M4LiOVI1OjJ|OECx
A2780 MojwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7vXnFvOC5yNT2yJO69VQ>? M3;Jd|ExNzJ2L{S4JIg> NUf4THI6TE2VTx?= MUHt[YRq[XSnczDndo94fGhiYYLy[ZN1KGmwIHGgZ49v[2WwdILheIlwdi1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? MVyyOFIzOzhyMR?=
SRA01/04  NXj6T|JyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PmOFAvOiEQvF2= M1Kz[|Q5KGh? MnzCSG1UVw>? M1HFSJN2eHC{ZYPz[ZMh[2WubDDwdo9tcW[ncnH0bY9vKHSqcn;1[4ghe3WycILld5NqdmdidHjlJHBKO0txQXv0MEBxOziPQWDLJIFv\CCHUluxM|Ihe2mpbnHsbY5oKHCjdHj3ZZl{ Mke5NlQyPTd6N{i=
HLEB3 Mn;nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLTVHMxNjJizszN M2jmVFQ5KGh? M3vDVWROW09? MVPzeZBxemW|c3XzJINmdGxicILvcIln\XKjdHnvckB1cHKxdXfoJJN2eHC{ZYPzbY5oKHSqZTDQTVNMN0GtdDygdFM5VUGSSzDhcoQhTVKNMT:yJJNq\26jbHnu[{Bx[XSqd3H5dy=> NYP0TndvOjRzNUe4O|g>
SRA01/04  NVqwdnZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXwPZVOOC52L{CuPEDPxE1? MWC0PEBp M2LtW2ROW09? M3jkN4lv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MnznNlQyPTd6N{i=
HLEB3 NFfkSYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;HXJpDOC52L{CuPEDPxE1? NUjlPJR[PDhiaB?= NVT1SmtCTE2VTx?= NFPaTo9qdmS3Y3XzJINmdGxiYYDvdJRwe2m| NXnvUnN1OjRzNUe4O|g>
HCT116 M4nadGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLpNE4zKM7:TR?= NIfnTWMyOiCq NHGzepNmdmijbnPld{Bk\WyuIHHwc5B1d3OrczDpcoR2[2WmIHL5JJJi\GmjdHnvci=> NHW2T5MzPDF{MkKzNS=>
CA46 M3jnXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHHTXQ{NzZxMUKvNlQwPDhibl2= Mo[xOFghcA>? NInJZ3RqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:wIHH0JFI1KGGwZDC0PEBvVcLi NGXKTYczPDB4NEm1NS=>
PMNs NGfaSYFHfW6ldHnvckBCe3OjeR?= NWm5Omg2OzBibl2= NGDaW5U1QCCq MkjXbY5pcWKrdIOg[YZn\XKxY4n0c5NqeyxiSFTBR{Bi[3Srdnn0fUBidmRiUnHjJIFkfGm4aYT5 MW[yN|k5QDZzNx?=
H1299 NWSyVmNqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVOxxsDPxE4EoB?= MnvvNlQwPDhxN{KgbC=> M{nCWYV1cGGwb3y= M{LQd4lv[3KnYYPld{Bk\WyuIHTlZZRpKGGodHXyJFI1cA>? M{XNNlI{QTF4NkC5
A549 NFvPWWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLVNE4zPS9yLkWvNUDPxE1? NYTYOG9KOjRxNEivO|IhcA>? MojQ[ZRp[W6xbB?= NWDqbHY3cW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJIlvKGOxbnPlcpRz[XSrb36gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= NUT4WmRSOjN6Nke5PVE>
H1299 MofBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\aNE4zPS9yLkWvNUDPxE1? NGf0dVEzPC92OD:3NkBp MVnleIhidm:u MlfWbY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIHnuJINwdmOnboTyZZRqd25iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? M1TrSFI{QDZ5OUmx
A549 MkXBRZBweHSxc3nzJGF{e2G7 NV;JbYdWOC53L{Gg{txO MofSOFghcA>? M1W4d4V1cGGwb3y= MoDSbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NYDXTGxROjN6Nke5PVE>
H1299 Mlj2RZBweHSxc3nzJGF{e2G7 M1rsOlAvPS9zIN88US=> M1\vUFQ5KGh? NXzFVZVZ\XSqYX7vcC=> MmXZbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? M3XyVlI{QDZ5OUmx
SUM149PT NVvWbGlzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfQTnUzNzdwNT:xNEDPxE1? NWqzd5R2PDhiaB?= NV7VNWJSTE2VTx?= NGq5cmNqdmS3Y3XzJINmdGxiZHXheIgh[XRiMjFOwG0hcW6|ZX7zbZRqfmWueR?= M1jkdFI{Pzl{NkO4
SUM190PT MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfyVIR7PTBxMUCwM|I2OCCwTR?= NY\OdHZXPDhiaB?= Mn;nSG1UVw>? NXHLWoxScW6mdXPld{Bk\WyuIHTlZZRpKGG2IEWwJI5OKHOnboPpeIl3\Wy7 NEnIOmQzOzd7Mk[zPC=>
HCT1 M4fvOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX6wMlIwOS5yL{WuNEDPxE1? MoT6NVIwOjRxM{[vOFghcA>? Ml3DbY5lfWOnczDj[YxtKGSnYYToJIlvKGOxbnPlcpRz[XSrb36tJIFv\CC2aX3lMYRmeGWwZHXueEBu[W6wZYK= NWLSfFl6OjN5N{CwNFA>
Lovo MmfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHq1eZQxNjJxMT6wM|UvOCEQvF2= M{G0e|EzNzJ2L{O2M|Q5KGh? NYfvOlVrcW6mdXPld{Bk\WyuIHTlZZRpKGmwIHPvcoNmdnS{YYTpc44uKGGwZDD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> MkLvNlM4PzByMEC=
AGS MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonONE4xOTVvMTFOwG0> M4S1TlczKGh? NYrQXGR2cW6mdXPld{Bk\WyuIHTlZZRpKGOxbnPlcpRz[XSrb36g[IVx\W6mZX70cJk> M{P6SFI{PzR3MEK0
Huh7 M2X1[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoC5NUDPxE1? M4CwflI1KGh? MUDEUXNQ MofvdoVlfWOnczDhZo92fCB{MDWgeoli[mmuaYT5xsA> MVyyN|Y1Ozl|Mx?=
ECC1 NVjpNIg{TnWwY4Tpc44hSXO|YYm= M3jUcFUxOCCwTR?= MlvuOUBl M3jqemROW09? MWLpcoR2[2W|IFyxR2FOyqCneIDy[ZN{cW:wIHPvMZRz\WG2bXXueEB4cXSqIEWtRZpiSw>? NITzZoIzOzV|MEe2PS=>
HEC1A MWXGeY5kfGmxbjDBd5NigQ>? Mnf3OVAxKG6P MnLzOUBl M{fEVWROW09? NEnyWXFqdmS3Y3XzJGwyS0GPwrDlfJBz\XO|aX;uJINwNXS{ZXH0cYVvfCC5aYToJFUuSXqjQx?= NHXHNo0zOzV|MEe2PS=>
EN1 Ml3PSpVv[3Srb36gRZN{[Xl? NVvBW3F5PTByIH7N NUjtWoRKPSCm MkTvSG1UVw>? Ml7vbY5lfWOnczDMNWNCVcLiZYjwdoV{e2mxbjDjc{11emWjdH3lcpQhf2m2aDC1MWF7[UN? M1;oO|I{PTNyN{[5
MFE296 NVz0[mRwTnWwY4Tpc44hSXO|YYm= MmjYOVAxKG6P MmjiOUBl M2jnVGROW09? NV3HXlNUcW6mdXPld{BNOUODTdMg[ZhxemW|c3nvckBkdy22cnXheI1mdnRid3n0bEA2NUG8YVO= MXuyN|U{ODd4OR?=
HASMCs NFTqTJNHfW6ldHnvckBCe3OjeR?= MXGwMVUxOCCwTR?= M{\wdlYh\A>? NGjXN4Nld3ewLYLl[5Vt[XSnczD0bIUh\XiycnXzd4lwdiCxZjDIRWREKGGwZDDj[YxtKH[rYXLpcIl1gQ>? MX[yN|UyQDR4Nx?=
U373 MlG0SpVv[3Srb36gRZN{[Xl? NFTZ[VYxNjJ3L{CuOU8yKM7:TR?= NUWwdJF2OjRiaB?= NYjzcVRQcW6lcnXhd4V{KFCULVKg[ZhxemW|c3nvckBkdy22cnXheI1mdnRid3n0bEA2SXqjZFO= MUmyN|Q4PDF5MR?=
ARN8  M2H0XmZ2dmO2aX;uJGF{e2G7 NX7KZYpIOC5yNT2yJO69VQ>? NE\aSYszPCCq MVHy[YR2[2W|IITo[UBqdmS3Y4Tpc44hd2ZicEWzMYRmeGWwZHXueEBo\W6nczDifUBPfXSuaX6tNy=> NYPQdpVHOjN2N{C1OFA>
MCF7 NI[wcpRHfW6ldHnvckBCe3OjeR?= MmTaNE4xPS1{IN88US=> NI\rdGszPCCq MYLy[YR2[2W|IITo[UBqdmS3Y4Tpc44hd2ZicEWzMYRmeGWwZHXueEBo\W6nczDifUBPfXSuaX6tNy=> MXWyN|Q4ODV2MB?=
H1299  NIfBdlhHfW6ldHnvckBCe3OjeR?= M{DVTVAvOzQkgKOxxsDDvU1? NEjNT5gzPC92ODDo MVTEUXNQ M{Padolv[3KnYYPld{BGNWOjZHjldolvKHC{b4TlbY4hdGW4ZXzzJIRwe2ViZHXw[Y5l\W62bIm= MnP5NlM1PjF7N{W=
H1299 MXXGeY5kfGmxbjDBd5NigQ>? MljyNE42KM7:TR?= M2GxUVQ5KGh? MlPPSG1UVw>? NYjPdGxKcW6qaXLpeJMhfGinIH3p[5JifG:{eTDwc5RmdnSrYXygZ49u[mmwZTD3bZRpKHOrbHnibY5qdg>? MVuyN|Q3OTl5NR?=
H1299 MVvGeY5kfGmxbjDBd5NigQ>? MX[wMlUh|ryP MWS0PEBp M2XPfWROW09? NEf5bYlqdmirYnn0d{B1cGViaX72ZZNqfmWwZYPzxsAh[2:vYnnu[UB4cXSqIIPpcIljcW6rbh?= MXiyN|Q3OTl5NR?=
MG-63  MoG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV21W21DOC5|IN88US=> M{TXRlEzNTl4IHi= NFLXRoJFVVOR MkLnbY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIHPvMZRz\WG2bXXueEB4cXSqIH3leIZwem2rbh?= M3H1clI{PDVzOEG3
LM8 M13TNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPvNE4{KM7:TR?= NEHGdnYyOi17NjDo NEPLepJFVVOR NWrMUIN6cW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJINwNXS{ZXH0cYVvfCC5aYToJI1mfG[xcn3pci=> MWGyN|Q2OThzNx?=
K562 NWPwdmZ2TnWwY4Tpc44hSXO|YYm= MYCwMlUh|ryP NG\3ZVIzPCCq MYLleIhidm:u MXXk[YNz\WG|ZYOgeIhmKGWweont[UBi[3Srdnn0fUBw\iCKRFHDd{Bkdy22cnXheI1mdnRid3n0bEBkfXKldX3pci=> M3XVWlI{PDNyOUW3
HEL MkPzSpVv[3Srb36gRZN{[Xl? NEOxbosxNjVizszN M2HrOFI1KGh? MoXx[ZRp[W6xbB?= NEDVVlhl\WO{ZXHz[ZMhfGinIHXufplu\SCjY4Tpeol1gSCxZjDISGFEeyClbz30doVifG2nboSge4l1cCCldYLjeY1qdg>? NVT6WHNPOjN2M{C5OVc>
HL60 MY\BdI9xfG:|aYOgRZN{[Xl? MlLuNUDPxE1? NY\jUJczOjRiaB?= Ml3abY5lfWOnc9MgZ4VtdCCmZXH0bC=> M4HTSVI{PDByNUG5
KG1 MUnBdI9xfG:|aYOgRZN{[Xl? Mm\SNUDPxE1? MWKyOEBp NF3aVmRqdmS3Y3XzxsBk\WyuIHTlZZRp M{nRNVI{PDByNUG5
Kazumi NYmxPItvSXCxcITvd4l{KEG|c3H5 MmLZNUDPxE1? M4nvPVI1KGh? NHnpOXdqdmS3Y3XzxsBk\WyuIHTlZZRp NULsV3d7OjN2MEC1NVk>
K562 M2[5ZmFxd3C2b4Ppd{BCe3OjeR?= M3zLO|Eh|ryP MV6yOEBp MUPpcoR2[2W|wrDj[YxtKGSnYYTo M3rtZlI{PDByNUG5
THP1 NEL4b3BCeG:ydH;zbZMhSXO|YYm= NHrFTIgyKM7:TR?= NHPaWYEzPCCq MWHpcoR2[2W|wrDj[YxtKGSnYYTo MUSyN|QxODVzOR?=
SH-SY5Y MXTGeY5kfGmxbjDBd5NigQ>? NYLlfIJ6OjVyIH7N NV7F[Jk{OTZiaB?= NWT1PYlR[2ijbnfld{BmgHC{ZYPzbY9vKHCjdITldo4hd2ZiZ3Xu[ZMhcW64b3z2[YQhcW5iY3jvcIV{fGW{b3ygd5lvfGinc3nzMEB2eHSja3WgZY5lKGWoZnz1fC=> NFXHdZczOzN{NkSyNi=>
HEK293 MmDDSpVv[3Srb36gRZN{[Xl? M2fmTlEhyrWPwrC= M{nzR|E5KGkEoB?= MmL3bY5pcWKrdIOgeIhmKGujbHnybY4uPy2vZXTpZZRm\CC{ZXPyeYl1dWWwdDDv[kB{gW6yaHnsbY4uOSCjZ3fy[YdifGW|IHnueI8h[WepcnXzc41mew>? M3;oeFI{Ojh2OES4
HTK M1W5TmZ2dmO2aX;uJGF{e2G7 M4\Kc|QxOCCwTR?= M3f2WVczKGh? Mn\4bY5pcWKrdIOgWGdHNc7{4pETTY5lfWOnZDDNfY9ncWK{b3LsZZN1KESrZn\ldoVvfGmjdHnvci=> MkLjNlMzQDRyMEK=
HTK M2T3O2Z2dmO2aX;uJGF{e2G7 MlTnNVAxNThyMH7N M1[0bFczKGh? NGfkXmpjdG:la4OgWGdHNc7{4pETTY5lfWOnZDDSU3Mh[W6mIFiyU|LDqEGlY4XteYxifGmxbh?= NVHYeZRDOjN{OESwNFI>
Caco-2  MVTGeY5kfGmxbjDBd5NigQ>? MX:xJOK2VcLi NVrOc4ZVOjRiaB?= NELjZlJl\WO{ZXHz[ZMhW0WUVDDwdo91\WmwIHX4dJJme3Orb36= MYWyN|E6PTB5MB?=
HeLa MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\wcGpCOTByIH7N MlG4NlQhcA>? NIXjOpBFVVOR M{jVWGlEPTBib3[gNVAxdk1? NYXzdZB2OjNzNkW3OFg>
HeLa M2TVbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDLRW81OCCwTR?= Mn7KOFghcA>? NY\mZZhVTE2VTx?= NEfTb4lKSzVyIH;mJFQxdk1? MoHQNlMyPjV5NEi=
HeLa NHu1flhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILESnUzOCCwTR?= NHvke3c4OiCq NV\u[|RYTE2VTx?= NFHyeIxKSzVyIH;mJFIxdk1? MX2yN|E3PTd2OB?=
HeLa Mo[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnifI8yOC9|MD:1NEBvVQ>? M{Czc|czKGh? MoPUSG1UVw>? MlL3bY5kemWjc3XzJJRp\SCwdX3i[ZIhd2ZiTV3QJEjPnM7qbTmgcI9{eyClZXzsd{Bld3OnIHTldIVv\GWwdHz5 M1i3bVI{OTZ3N{S4
MDA-MB-231 MlPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzW[4EzPS12MECgcm0> M{nGd|Q5KGh? NYjiZ3lzUUN3MDDv[kAzPjNwMn7NxsA> MlzGNlMxPTVzOUi=
MCF-7  Ml34S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHMbFEzPS12MECgcm0> MmjaOFghcA>? NX61UYhnUUN3MDDv[kAzOjBwNH7N MnK0NlMxPTVzOUi=
ECC-1  M4ezb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGL1fY8yODBibl2= NF32XVMzPCCq MkX2[ZRp[W6xbB?= MlvjbY5kemWjc3XzJJRp\SCycn;wc5J1cW:wIH;mJIFxd3C2b4TpZ{BvfWOuZXmgeI8hOzVn M1\HTFI{ODJ6OECz
HEC-1A NGjEdYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU[0R5JMOTByIH7N NWjZSFI6OjRiaB?= NEKwc5BmfGijbn;s M4[0R4lv[3KnYYPld{B1cGVicILvdI9zfGmxbjDv[kBieG:ydH;0bYMhdnWlbHXpJJRwKDN7JR?= MkfQNlMxOjh6MEO=
NHAC-kn Mmn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHBNVAwOTByL{WwNEBvVQ>? NGSxUGYyOiCq NIfydmtFVVOR MXvJR|UxKG:oIEWwNI5O M2TKbFI{ODF5OEex
A549 M2TvUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTOXoVOOjVyIH7N Mn;tOk04OiCq NXXY[5FXTE2VTx?= MmnyZ4F2e2W|IHGg[5Jm[XSncjDpcohq[mm2b4L5JIVn\mWldDDjc41jcW6nIIfpeIghXFiWIH;yJIVzdG:2aX7pZi=> MWiyNlk6PDd6MB?=
MG-63 Mn3rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUCzNFAhdk1? NEK2c4oyOiCq M3\mdWROW09? MYrpcohq[mm2czD0bIUh[2WubDDndo94fGhidH:gPFYm NILwPWgzOjd7OUOzPC=>
MG-63 M4XWSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUD2b|g2OzByIH7N NXnYS296OjRiaB?= MmHxSG1UVw>? M1HybYlvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDD0c{A3PyV? M3TpUFIzPzl7M{O4
MG-63 NI\wd41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzrSI8{ODBibl2= Mlu3OFghcA>? MY\EUXNQ M4nHXYlvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDD0c{A2PiV? MmG5NlI4QTl|M{i=
HL60  MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHIN|cyPTBvM{WwJI5O MX:yOEBp NVr2clU1cW6lcnXhd4V{KGOnbHygZZBweHSxc3nzxsB4cGWwIHPvcoNmdnS{YYTpc45{KGirZ3jldkB1cGGwIEK1NEBvVQ>? MVyyNlc2Ozd|OR?=
U937 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfzfnl5OTVyLUO1NEBvVQ>? NILzXnIzPCCq NVvTWnFOcW6lcnXhd4V{KGOnbHygZZBweHSxc3nzxsB4cGWwIHPvcoNmdnS{YYTpc45{KGirZ3jldkB1cGGwIEK1NEBvVQ>? NUjZNYZvOjJ5NUO3N|k>
SCC-6 Ml\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvhNlAxNTN{MECgcm0> MkW5NVIwOjRxNEigbC=> MYDEUXNQ NEXsOWlqdmirYnn0d{B1cGVicILvcIln\XKjdHnvckBw\iCVQ1OtOkBk\WyuczDpckBiKGSxc3WtJIFv\CC2aX3lMYRmeGWwZHXueEBu[W6wZYK= M1XJclIzPTV{M{Kx
U87  NYXpS|hIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XiPVExOC1|MECgcoc> Ml3WNlQhcA>? M{DLNolvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDD0c{A4OiViIHH0JFIxOG6p MVOyNlI4ODh2OR?=
K562 MXPGeY5kfGmxbjDBd5NigQ>? NILhS5kyKM7:TR?= MVKxNkBp M4rtXmROW09? Mnvm[Y5p[W6lZYOgeIhmKGW6cILld5Nqd25ib3[gVnVPYDNiaX7keYNm\CCkeTC1MYF7[S2FZGK= NUDtb4RPOjJzN{mxPVg>
Reh NUHnVIZvTnWwY4Tpc44hSXO|YYm= MYqwMlMwOSEQvF2= NIjCNnEyOiCq NGjmcJRFVVOR NELqOYJmdmijbnPld{B1cGViZYjwdoV{e2mxbjDv[kBTXU6[MzDpcoR2[2WmIHL5JFUu[XqjLVPkVi=> MnfRNlIyPzlzOUi=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
EGFR / STAT3 ; 

PubMed: 31289542     


Expression of EGFR and STAT3 in PC3 cells treated with TSA. PC3 cells were plated in 6-cm dishes, and 0.25, 0.5 or 1 µM TSA was added for 24 h. DMSO was added into the control group wells. Cells were collected and lysed with lysis buffer and the protein expression analyzed via western blotting.

Cyclin D1 / CDK6 / CDK4 / p-RB / RB; 

PubMed: 31289542     


Expression of cyclin D1, CDK6, CDK4 and RB, and the phosphorylation of RB, was detected in PC3 cells treated with TSA for 24 h. 

MMP-1 / MMP-3 / MMP-13 / TIMP-1; 

PubMed: 27431944     


Chondrocytes were pretreated with increasing concentrations of TSA for 2 h, followed by stimulation with 5 ng/ml IL-1β for 24 h.

Acetyl-H3 (Lys27) / H3 (96C10) / Acetyl-H4(Lys8) / H4(L64C1); 

PubMed: 27431944     


Chondrocytes were treated with increasing concentrations of TSA for 24 h.

α-H3Ac / α-H4Ac / α-H3K9Ac / α-H3K9 S10 / α-H3K4 me / α-H3K4 me2 / α-H3K9 me2; 

PubMed: 23802098     


Histone acetylation occurs directly at the promoter region of IL-23R. The ChIP assay demonstrates that TSA treatment results in an increase in the acetylation of histone H3 and H4. A549 cells were cultured in the presence or absence of TSA (250 ng/mL) for a period of 24 h. Subsequently, a ChIP assay was performed using the following antibodies; pan acetyl-histone H3 (H3Ac), pan acetyl-histone H4 (H4Ac), acetyl-histone H3 Lys 9 (H3K9Ac), acetyl-histone H3 Lys 9/14 (H3K9/14ac), acetyl-histone H3 Lys 9 phosphoSer10 (H3K9S10), methyl-histone H3 Lys 4 (H3K4Me), di methyl-histone H3 Lys 4 (H3K4Me2), and di methyl-histone H3 Lys 9 (H3K9Me2). Input DNA serves as a positive control as recommended by the manufacturer (Diagenode). A no antibody control was included to test for non-specific binding (UT, untreated; TSA, Trichostatin A).

31289542 27431944 23802098
Immunofluorescence
α-C/EBPβ / α-HP1α ; 

PubMed: 21122806     


3T3-L1 preadipocytes were grown on coverslips for three days and induced to differentiate by treatment with MDI (48 h) in the presence of vehicle (-TSA) or 87 nM Trichostatin A (+TSA). Under these experimental conditions: A-H Cells were fixed and permeabilized in cold methanol, subjected to IIF with the indicated antibodies, and nuclei were counterstained with DAPI. Scale bar, 5 μm. 

α-HDAC1 ; 

PubMed: 29045501     


MCF-7 cells were treated with indicated concentrations of trichostatin A (optical sections E-H, respectively) for 12 hours, fixed, permeabilized and optical sections were obtained by laser scanning confocal microscopy. Fluorescence signal for HDAC1 is shown in green (left panels), DAPI staining is shown in blue (middle panels), and merged optical sections are shown in the right panels.

α-tubulin / acetylated histone 3; 

PubMed: 27957719     


Immunocytochemistry for acetylated α-tubulin (red) and acetylated histone 3 (green) on N2a cells treated with 1 μM TSA, ACY-738, and ACY-775.

21122806 29045501 27957719
Growth inhibition assay
Cell viability (A549 cells); 

PubMed: 27571418     


Cytotoxicity of histamine determined by MTT assay in A549 cells.

Cell viability (MDA-MB-231 cells); 

PubMed: 27548148     


The human breast cancer cells (MDA-MB-231) were incubated with various concentrations of TSA (0–300 nM) for 24 h. Cell viability was measured by WST-8.

Cell viability (PC3 cells); 

PubMed: 31289542     


PC3 cells were plated in a 96-well plate and treated with different doses of TSA (0, 0.25, 0.5 and 1 µM) for 72 h; an MTT assay was used to measure the effects of TSA on PC3 cell proliferation.

27571418 27548148 31289542
In vivo Administration of Trichostatin A at 0.5 mg/kg for 4 weeks displays potent antitumor activity in the N-methyl-N-nitrosourea carcinogen-induced rat mammary carcinoma model, without any measurable toxicity at doses up to 5 mg/kg. [1] Single intraperitoneal doses of 10 mg/kg Trichostatin A in nontransgenic and spinal muscular atrophy (SMA) model mice results in increased levels of acetylated H3 and H4 histones and modest increases in survival motor neuron (SMN) gene expression. Administration of Trichostatin A at 10 mg/kg/day improves survival, attenuates weight loss, and enhances motor behavior in the SMA model mice. [5]

Protocol

Kinase Assay:

[1]

- Collapse

In vitro HDAC activity:

Total cellular extracts are prepared from each breast cancer cell line (MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, or SK-BR-3). A 20 μL crude cell extract (~2.5 ×105 cells), in the presence of varying concentrations of Trichostatin A in 0.1% (v/v) ethanol or 0.1% (v/v) ethanol as vehicle control, are incubated for 60 minutes at 25 °C with 1 μL (~1.5 × 106 cpm) of [3H]acetyl-labeled histone H4 peptide substrate (NH2-terminal residues 2-20) that has been acetylated with [3H]acetic acid, sodium salt (3.7 GBq/mmol) by an in vitro incorporation method. Each 200 μL reaction is quenched with 50 μL of 1 M HCl/0.16 M acetic acid and extracted with 600 μL of ethyl acetate, and released [3H]acetate is quantified by scintillation counting. IC50 values are determined graphically using nonlinear regression to fit inhibition data to the appropriate dose-response curve.
Cell Research:

[1]

- Collapse
  • Cell lines: MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3
  • Concentrations: Dissolved in absolute ethanol, final concentrations ~10 μM
  • Incubation Time: 96 hours
  • Method:

    Cells are exposed to various concentrations of Trichostatin A for 96 hours. After treatment, cell proliferation is estimated using the sulforhodamine B colorimetric assay. Cell viability is determined by trypan blue exclusion.


    (Only for Reference)
Animal Research:

[1]

- Collapse
  • Animal Models: Inbred virgin female (Ludwig/Wistar/Olac) rats bearing tumors induced with NMU
  • Dosages: ~5 mg/kg/day
  • Administration: Injection s.c.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 23 mg/mL (76.05 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+2% Tween 80+ddH2O
For best results, use promptly after mixing.
3mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 302.4
Formula

C17H22N2O3

CAS No. 58880-19-6
Storage powder
in solvent
Synonyms N/A

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03901053 Recruiting Device: Reaktiv AFO|Device: PhatBrace AFO Foot Injuries and Disorders Jason Wilken|Minneapolis Veterans Affairs Medical Center|Walter Reed National Military Medical Center|Henry M. Jackson Foundation for the Advancement of Military Medicine|Center for Veterans Research and Education|University of Delaware|Johns Hopkins Bloomberg School of Public Health|University of Iowa February 27 2020 Not Applicable
NCT03887650 Recruiting Drug: Liposomal Bupivicaine 1.3%|Drug: Bupivacaine 0.5% Post-operative Pain|Total Shoulder Arthroplasty|Osteoarthritis of the Shoulder|Pain Management Hartford Hospital January 14 2019 Phase 4
NCT03838926 Recruiting Drug: Trichostatin A Relapsed or Refractory Hematologic Malignancies Vanda Pharmaceuticals September 27 2018 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to obtain the enantiomers of TSA, as separate chemicals: R-TSA and S-TSA. Do you have any ideas?

  • Answer:

    Our S1045 Trichostatin A (TSA) is R enantiomer.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Trichostatin A|Trichostatin A ic50|Trichostatin A price|Trichostatin A cost|Trichostatin A solubility dmso|Trichostatin A purchase|Trichostatin A manufacturer|Trichostatin A research buy|Trichostatin A order|Trichostatin A mouse|Trichostatin A chemical structure|Trichostatin A mw|Trichostatin A molecular weight|Trichostatin A datasheet|Trichostatin A supplier|Trichostatin A in vitro|Trichostatin A cell line|Trichostatin A concentration|Trichostatin A nmr|Trichostatin A in vivo|Trichostatin A clinical trial|Trichostatin A inhibitor|Trichostatin A Epigenetics inhibitor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID